bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 5 from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types
Authors: Topham James T. , Titmuss Emma , Pleasance Erin D. , Williamson Laura M. , Karasinska Joanna M. , Culibrk Luka , Lee Michael K.C. , Mendis Shehara , Denroche Robert E. , Jang Gun-Ho , Kalloger Steve E. , Wong Hui-Li , Moore Richard A. , Mungall Andrew J. , O'Kane Grainne M. , Knox Jennifer J. , Gallinger Steven , Loree Jonathan M. , Mager Dixie L. , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Schaeffer David F. , Renouf Daniel J.
Published: April 2023

Supplemental Table S5 lists EGA accession numbers for each sample included in the study.
Supplementary Table 3 from Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types
Authors: Topham James T. , Titmuss Emma , Pleasance Erin D. , Williamson Laura M. , Karasinska Joanna M. , Culibrk Luka , Lee Michael K.C. , Mendis Shehara , Denroche Robert E. , Jang Gun-Ho , Kalloger Steve E. , Wong Hui-Li , Moore Richard A. , Mungall Andrew J. , O'Kane Grainne M. , Knox Jennifer J. , Gallinger Steven , Loree Jonathan M. , Mager Dixie L. , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Schaeffer David F. , Renouf Daniel J.
Published: April 2023

Supplemental Table S3 lists gene sets significantly enriched among genes up-regulated in VMP samples.
Supplementary Data from Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
Authors: Tewari Krishnansu S. , Sill Michael W. , Monk Bradley J. , Penson Richard T. , Moore David H. , Lankes Heather A. , Ramondetta Lois M. , Landrum Lisa M. , Randall Leslie M. , Oaknin Ana , Leitao Mario M. , Eisenhauer Eric L. , DiSilvestro Paul , Van Le Linda , Pearl Michael L. , Burke James J. , Salani Ritu , Richardson Debra L. , Michael Helen E. , Kindelberger David W. , Birrer Michael J.
Published: April 2023

FIGURE S1
Supplementary Figures 1-13 and Supplementary Materials and Methods from The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor
Authors: Andreano Kaitlyn J. , Baker Jennifer G. , Park Sunghee , Safi Rachid , Artham Sandeep , Oesterreich Steffi , Jeselsohn Rinath , Brown Myles , Sammons Sarah , Wardell Suzanne E. , Chang Ching-yi , Norris John D. , McDonnell Donald P.
Published: April 2023

Supplemental Figure 1: Structures of clinically relevant compounds used in this study. Supplemental Figure 2: Cells expressing both the ERWT and ERmuts have similar pharmacological responses to antiestrogens when compared to cells only expressing ERWT. Supplemental Figure 3: Albeit differences in clonal variability, there is indistinguishable differences in T47D proliferation in response to antiestrogens. Supplemental Figure 4: Downregulation of ER in MCF7B cells is unaffected by the presence of the mutant receptor. Supplemental Figure 5: Validation of ER mutation status in engineered cell lines. Supplemental Figure 6: Protein levels of transfected constructs in SKBR3 cells are consistent with MCF7 expression level. Supplemental Figure 7: ER expression in MCF7I cells is titratable with doxycycline treatment. Supplemental Figure 8: Overexpression of ERY537S or ERD538G, not ERWT, in MCF7I cells changes ligand potency. Supplemental Figure 9: Western blot validation of relative ER expression levels in SKBR3. Supplemental Figure 10: Agonist activation of relative expression levels of ERWT and ERmuts in SKBR3 cells. Supplemental Figure 11: In-Cell Western validation of ER expression levels for siRNA knockdown and cDNA overexpression in MCF7i. Supplemental Figure 12: Agonist activation of relative expression levels of ERWT and ERmuts in MCF7i cells. Supplemental Figure 13: The altered potency of fulvestrant against the ERmuts on endogenous ER target genes is only evident when expressed at a level higher than the WT receptor.
Supplementary Table 1 and Figure S1- S8 from Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor
Authors: Adelaiye-Ogala Remi , Gryder Berkley E. , Nguyen Yen Thi Minh , Alilin Aian Neil , Grayson Adlai R. , Bajwa Wardah , Jansson Keith H. , Beshiri Michael L. , Agarwal Supreet , Rodriguez-Nieves Jose Antonio , Capaldo Brian , Kelly Kathleen , VanderWeele David J.
Published: April 2023

Supplementary Figure 1. Assessment of ipatasertib as single agent across models representing hormone sensitive PCa in vitro. Supplementary Figure 2. Assessment of ipatasertib on GR expression. Supplementary Figure 3. Western blot indicating effects of inhibitors on PI3K/AKT/mTOR signaling in LREX cell lines.Supplementary Figure 4. (A) Efficient knockdown of GR gene (NR3C1) and protein in LREX cells as indicated by qRT-PCR and western blot. Cell viability assay using LREX cells indicates no added effect when combining ipatasertib and enzalutamide compared to non silencing control following NR3C1 knockdown. (B) Quantitative RT-PCR and western blot indicating exogeneous overexpression of GR in engineered LNCAP and LREX cell lines. Cell viability assay indicates decreased response to ipatasertib in LNCaP and LREX cells overexpressing GR compared to control cells (Right panel). (C) 22RV1 cells have constitutively high GR expression that is not decreased with ipatasertib (right panel) and have marginal response to ipatasertib (left panel).
Suppl. Figs. 1-8 from Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination–Proficient Pancreatic Cancer
Authors: Parsels Leslie A. , Engelke Carl G. , Parsels Joshua , Flanagan Sheryl A. , Zhang Qiang , Tanska Daria , Wahl Daniel R. , Canman Christine E. , Lawrence Theodore S. , Morgan Meredith A.
Published: April 2023

Suppl. Figs. 1-8
Supplementary Data from Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer
Authors: Goel Sanjay , Ocean Allyson J. , Parakrama Ruwan Y. , Ghalib Mohammad H. , Chaudhary Imran , Shah Umang , Viswanathan Sengottuvel , Kharkwal Himanshu , Coffey Matthew , Maitra Radhashree
Published: April 2023

Supplementary table 1
Supplementary Data from Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer
Authors: Goel Sanjay , Ocean Allyson J. , Parakrama Ruwan Y. , Ghalib Mohammad H. , Chaudhary Imran , Shah Umang , Viswanathan Sengottuvel , Kharkwal Himanshu , Coffey Matthew , Maitra Radhashree
Published: April 2023

Supplementary table 2
Supplementary Data from Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer
Authors: Goel Sanjay , Ocean Allyson J. , Parakrama Ruwan Y. , Ghalib Mohammad H. , Chaudhary Imran , Shah Umang , Viswanathan Sengottuvel , Kharkwal Himanshu , Coffey Matthew , Maitra Radhashree
Published: April 2023

Supplementary Figures
Supplementary Methods from Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Authors: Kulukian Anita , Lee Patrice , Taylor Janelle , Rosler Robert , de Vries Peter , Watson Daniel , Forero-Torres Andres , Peterson Scott
Published: April 2023

Supplementary Methods
Supplementary Figures S1-S2 and Supplementary Table S1-S2 from Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Authors: Kulukian Anita , Lee Patrice , Taylor Janelle , Rosler Robert , de Vries Peter , Watson Daniel , Forero-Torres Andres , Peterson Scott
Published: April 2023

Supplementary Figure S1: Comparative potency of tucatinib, neratinib, and lapatinib in cellular HER2 and EGFR phosphorylation assays; Supplementary Figure S2: Effect of tucatinib, trastuzumab, or combination treatment on mouse body weight in HER2+ PDX models; Supplementary Table S1: Tucatinib activity correlates with HER2 surface receptor density; Supplementary Table S2. HER2 copy number variation in PDX models
Supplementary RNAseq Data from SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Authors: Shomali Maysoun , Cheng Jane , Sun Fangxian , Koundinya Malvika , Guo Zhuyan , Hebert Andrew T. , McManus Jessica , Levit Mikhail N. , Hoffmann Dietmar , Courjaud Albane , Arrebola Rosalia , Cao Hui , Pollard Jack , Lee Joon Sang , Besret Laurent , Caron Anne , Bangari Dinesh S. , Abecassis Pierre-Yves , Schio Laurent , El-Ahmad Youssef , Halley Frank , Tabart Michel , Certal Victor , Thompson Fabienne , McCort Gary , Filoche-Rommé Bruno , Cheng Hong , Garcia-Echeverria Carlos , Debussche Laurent , Bouaboula Monsif
Published: April 2023

1022 gene signature from RNAseq
Supplemental Table S1 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Authors: Werfel Thomas A. , Hicks Donna J. , Rahman Bushra , Bendeman Wendy E. , Duvernay Matthew T. , Maeng Jae G. , Hamm Heidi , Lavieri Robert R. , Joly Meghan M. , Pulley Jill M. , Elion David L. , Brantley-Sieders Dana M. , Cook Rebecca S.
Published: April 2023

Supplemental Table S1. Kaplan-Meier analysis of clinical cancer expression datasets (RNA-Seq) to assess the relationship between disease free patient survival and TBXA2R expression levels, as determined using Kmplot.com software, using the software-generated auto-select best cutoff for TBXA2R expression. N = the number of tumors with correlating clinical patient data. HR = hazard ratio. P value calculated using Log-Rank test.
Figure S3 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Authors: Werfel Thomas A. , Hicks Donna J. , Rahman Bushra , Bendeman Wendy E. , Duvernay Matthew T. , Maeng Jae G. , Hamm Heidi , Lavieri Robert R. , Joly Meghan M. , Pulley Jill M. , Elion David L. , Brantley-Sieders Dana M. , Cook Rebecca S.
Published: April 2023

Flow chart depicting the decision making steps towards selecting TBXA2R as a potential therapeutic target for drug repurposing of CPI211.
Figure S2 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Authors: Werfel Thomas A. , Hicks Donna J. , Rahman Bushra , Bendeman Wendy E. , Duvernay Matthew T. , Maeng Jae G. , Hamm Heidi , Lavieri Robert R. , Joly Meghan M. , Pulley Jill M. , Elion David L. , Brantley-Sieders Dana M. , Cook Rebecca S.
Published: April 2023

The effect of U46619 and CPI211 on migration and invasion of 4T1 and MDA-MB-231 tumor cells through Matrigel-coated transwells was assessed. Tumor cells were seeded in the upper chambers of a Matrigel-coated transwell insert in serum-free media. Cell migration towards 1% serum in the lower chamber was assessed by crystal violet staining of the lower side of the transwell filter. Digital images of stained transwell filters were used to count the number of migrated cells. Representative images are shown (A). Each data point shown (B) represents the number of cells migrating to the lower side of the filter. Midlines are the average {plus minus} S.D., N = 4 (4T1) and 5 (MDA-MB-231), each assessed in triplicate.
Supplementary Data from Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma
Authors: Huq Sakibul , Casaos Joshua , Serra Riccardo , Peters Michael , Xia Yuanxuan , Ding Andy S. , Ehresman Jeff , Kedda Jayanidhi N. , Morales Manuel , Gorelick Noah L. , Zhao Tianna , Ishida Wataru , Perdomo-Pantoja Alexander , Cecia Arba , Ji Chenchen , Suk Ian , Sidransky David , Brait Mariana , Brem Henry , Skuli Nicolas , Tyler Betty
Published: April 2023

Supplementary Figures 1-6
Figure S1 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Authors: Werfel Thomas A. , Hicks Donna J. , Rahman Bushra , Bendeman Wendy E. , Duvernay Matthew T. , Maeng Jae G. , Hamm Heidi , Lavieri Robert R. , Joly Meghan M. , Pulley Jill M. , Elion David L. , Brantley-Sieders Dana M. , Cook Rebecca S.
Published: April 2023

Chemical structure of CPI211 is shown in Panel A. Western analysis of 293T cells expressing lentiviral empty vector, TPr-WT, or TPr-T399A s shown in Panel B. Antibodies used are shown to the left of each panel.
Supplementary figures from Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models
Authors: Kato Takuya , Okada Ryuhei , Furusawa Aki , Inagaki Fuyuki , Wakiyama Hiroaki , Furumoto Hideyuki , Okuyama Shuhei , Fukushima Hiroshi , Choyke Peter L. , Kobayashi Hisataka
Published: April 2023

Supplementary figure S1-S5
Table S2 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Authors: Arai Hiroyuki , Baca Yasmine , Battaglin Francesca , Kawanishi Natsuko , Wang Jingyuan , Soni Shivani , Zhang Wu , Millstein Joshua , Johnston Curtis , Goldberg Richard M. , Philip Philip A. , Seeber Andreas , Xiu Joanne , Hwang Jimmy J. , Shields Anthony F. , Marshall John L. , Korn W. Michael , Lenz Heinz-Josef
Published: April 2023

Copy number alteration frequency in appendiceal adenocarcinoma, NET and GCC
Supplementary Data from Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
Authors: Wang Anlai , Song Zhili , Zheng Gang , Nicolazzi Celine , Fromm Jonathan R. , Shehu Elvis , Srinivasan Srimathi , Chen Xueyan , Zhu Chen , Blondel Marielle Chiron , Adrian Francisco J.
Published: April 2023

Supplementary data
Figure S3 from Molecular Characterization of Appendiceal Goblet Cell Carcinoid
Authors: Arai Hiroyuki , Baca Yasmine , Battaglin Francesca , Kawanishi Natsuko , Wang Jingyuan , Soni Shivani , Zhang Wu , Millstein Joshua , Johnston Curtis , Goldberg Richard M. , Philip Philip A. , Seeber Andreas , Xiu Joanne , Hwang Jimmy J. , Shields Anthony F. , Marshall John L. , Korn W. Michael , Lenz Heinz-Josef
Published: April 2023

MCP-counter results for the three appendiceal tumor groups
Supplementary Table S4 from Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
Authors: García-Valverde Alfonso , Rosell Jordi , Serna Garazi , Valverde Claudia , Carles Joan , Nuciforo Paolo , Fletcher Jonathan A. , Arribas Joaquín , Politz Oliver , Serrano César
Published: April 2023

Drug combination effect of imatinib and copanlisib.
Supplementary Materials from Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies
Authors: Herrick William G. , Kilpatrick Casey L. , Hollingshead Melinda G. , Esposito Dominic , O'Sullivan Coyne Geraldine , Gross Andrea M. , Johnson Barry C. , Chen Alice P. , Widemann Brigitte C. , Doroshow James H. , Parchment Ralph E. , Srivastava Apurva K.
Published: April 2023

This document includes Supplementary Methods, validation data (Figures S1 and S2), complete PD data sets (Figures S3-S7), and Supplementary Tables detailing statistical analyses and assay validation.
Supplementary Table S2 from Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
Authors: García-Valverde Alfonso , Rosell Jordi , Serna Garazi , Valverde Claudia , Carles Joan , Nuciforo Paolo , Fletcher Jonathan A. , Arribas Joaquín , Politz Oliver , Serrano César
Published: April 2023

Individual IC50s values of copanlisib and imatinib in cell viability and proliferation studies in GIST-T1, GIST-T1/670 and GIST430/654.
Supplementary Data from Inhibition of Intermedin (Adrenomedullin 2) Suppresses the Growth of Glioblastoma and Increases the Antitumor Activity of Temozolomide
Authors: Huang Luping , Wang Denian , Feng Zhongxue , Zhao Huan , Xiao Fei , Wei Yong'gang , Zhang Heng , Li Hongyu , Kong Lingmiao , Li Min , Liu Fei , Zhang Haili , Zhang Wei
Published: April 2023

Supplementary Data
Supplementary Figure S2 from Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
Authors: García-Valverde Alfonso , Rosell Jordi , Serna Garazi , Valverde Claudia , Carles Joan , Nuciforo Paolo , Fletcher Jonathan A. , Arribas Joaquín , Politz Oliver , Serrano César
Published: April 2023

Plasma levels of copanlisib of GIST-T1 and GIST-T1/670 xenografts at day 21. Plasma was collected 4 hours after last drug administration.
Supplemental Figure 2 from Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch
Authors: Goka Erik T. , Chaturvedi Pallavi , Lopez Dayrelis T. Mesa , Lippman Marc E.
Published: April 2023

Supplemental Figure 2. HACE1 overexpression reduces activated Rac1 and attenuates ccRCC growth and survival. (A) Rac1 and HACE1 mRNA expression correlation from the KIRC TCGA Dataset (B) Rac1-GTP Pull-down assay of empty vector or HACE1 overexpressing 786-O cells. (C) Migration assay on empty vector or HACE1 overexpressing 786-O cells. (D) Cellular proliferation assay of empty vector or HACE1 overexpressing 786-O cells. (E) Soft agar assay results of empty vector or HACE1 overexpressing 786-O cells.
Table S5 from An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities
Authors: Nicolazzi Céline , Caron Anne , Tellier Alexia , Trombe Marc , Pinkas Jan , Payne Gillian , Carrez Chantal , Guérif Stéphane , Maguin Marie , Baffa Raffaele , Fassan Matteo , Adam Julien , Mangatal-Wade Lydie , Blanc Véronique
Published: April 2023

IHC detection in normal human tissues of MUC1 glycoprotein and CA6 glycotope
Supplementary Table 1 from Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12
Authors: Lewis Nuruddeen D. , Sia Chang Ling , Kirwin Katherine , Haupt Sonya , Mahimkar Gauri , Zi Tong , Xu Ke , Dooley Kevin , Jang Su Chul , Choi Bryan , Boutin Adam , Grube Andrew , McCoy Christine , Sanchez-Salazar Jorge , Doherty Michael , Gaidukov Leonid , Estes Scott , Economides Kyriakos D. , Williams Douglas E. , Sathyanarayanan Sriram
Published: April 2023

Mean Cytokine Values in Cynomolgus Plasma After Subcutaneous Dosing
Mat & Met S6 from An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities
Authors: Nicolazzi Céline , Caron Anne , Tellier Alexia , Trombe Marc , Pinkas Jan , Payne Gillian , Carrez Chantal , Guérif Stéphane , Maguin Marie , Baffa Raffaele , Fassan Matteo , Adam Julien , Mangatal-Wade Lydie , Blanc Véronique
Published: April 2023

In vivo efficacy parameters
Supplementary Data from Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis
Authors: Xie Xuemei , Lee Jangsoon , Liu Huey , Pearson Troy , Lu Alexander Y. , Tripathy Debu , Devi Gayathri R. , Bartholomeusz Chandra , Ueno Naoto T.
Published: April 2023

Supplementary Data
Supplementary Tables 1-3 from Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Authors: Morrison-Smith Chevaun D. , Knox Tatiana M. , Filic Ivona , Soroko Kara M. , Eschle Benjamin K. , Wilkens Margaret K. , Gokhale Prafulla C. , Giles Francis , Griffin Andrew , Brown Bill , Shapiro Geoffrey I. , Zucconi Beth E. , Cole Philip A. , Lemieux Madeleine E. , French Christopher A.
Published: April 2023

Supplemental Table S1. Statistical analysis of survival in PER-403 model, full study. Supplemental Table S2. Statistical analysis of survival in 10-15 mouse model, full study. Supplemental Table S3. Statistical analysis of survival in 14169 model, full study.
Figure S1 from An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities
Authors: Nicolazzi Céline , Caron Anne , Tellier Alexia , Trombe Marc , Pinkas Jan , Payne Gillian , Carrez Chantal , Guérif Stéphane , Maguin Marie , Baffa Raffaele , Fassan Matteo , Adam Julien , Mangatal-Wade Lydie , Blanc Véronique
Published: April 2023

Indirect flow cytometry binding curves for huDS6 and SAR566658
Supplementary Methods from Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Authors: Morrison-Smith Chevaun D. , Knox Tatiana M. , Filic Ivona , Soroko Kara M. , Eschle Benjamin K. , Wilkens Margaret K. , Gokhale Prafulla C. , Giles Francis , Griffin Andrew , Brown Bill , Shapiro Geoffrey I. , Zucconi Beth E. , Cole Philip A. , Lemieux Madeleine E. , French Christopher A.
Published: April 2023

Supplemental methods
Supplementary Fig S6 from CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
Authors: Zeng Ling , Nikolaev Anatoly , Xing Chuan , Della Manna Deborah L. , Yang Eddy S.
Published: April 2023

Figure S6 shows differential effects of prexasertib on proliferation of prexasertib-sensitive and prexasertib-resistant cells.
Supplementary Fig S5 from CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
Authors: Zeng Ling , Nikolaev Anatoly , Xing Chuan , Della Manna Deborah L. , Yang Eddy S.
Published: April 2023

Figure S5 shows an in vivo pilot study with UM-SCC1-Luc and combination treatment toxicity as assessed by body weight in mice bearing HNSCC xenografts
Supplementary Data from Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Authors: Morrison-Smith Chevaun D. , Knox Tatiana M. , Filic Ivona , Soroko Kara M. , Eschle Benjamin K. , Wilkens Margaret K. , Gokhale Prafulla C. , Giles Francis , Griffin Andrew , Brown Bill , Shapiro Geoffrey I. , Zucconi Beth E. , Cole Philip A. , Lemieux Madeleine E. , French Christopher A.
Published: April 2023

Supplemental Tables
Supplementary Fig S3 from CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
Authors: Zeng Ling , Nikolaev Anatoly , Xing Chuan , Della Manna Deborah L. , Yang Eddy S.
Published: April 2023

Figure S3 shows a cell cycle analysis in HNSCCs
Supplemental Figures 1-9 from Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Authors: Morrison-Smith Chevaun D. , Knox Tatiana M. , Filic Ivona , Soroko Kara M. , Eschle Benjamin K. , Wilkens Margaret K. , Gokhale Prafulla C. , Giles Francis , Griffin Andrew , Brown Bill , Shapiro Geoffrey I. , Zucconi Beth E. , Cole Philip A. , Lemieux Madeleine E. , French Christopher A.
Published: April 2023

Supplemental Figure S1: NEO2734 induces differentiation in 10-15 cells. Supplemental Figure S2: Caspase-mediated apoptosis plays a minimal role in the activity of GNE-781, OTX015, or NEO2734. Supplemental Figure S3: BRD4-NUT protein levels decrease slightly upon exposure to NEO2734. Supplemental Figure S4: Global H3K27Ac levels do not change upon exposure to NEO2734. Supplemental Fig. S5. BRD4-NUT foci diminish over time course in TC-797 cells. Images were taken at identical magnification (1000x) with identical exposure settings per stain. Supplemental Figure S6. Dot plots of fold change of gene expression in samples treated with the indicated compound versus that in DMSO-treated samples. Supplemental Figure S7: Proportion of differentially expressed genes overlapping BRD4-NUT megadomains is greater in genes whose expression is downregulated in the presence of p300/CBP and/or BET bromodomain inhibition. Supplemental Figure S8: Tolerability in the full 10-15 mouse xenograft study. Supplemental Figure S9: Cleaved PARP is unchanged, but BRD4-NUT is somewhat depleted in mouse xenograft tumors exposed to NEO2734.
Supplementary Data from The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation
Authors: Jiang Yuchen , Peng Xia , Ji Yinchun , Dai Yang , Fang Yanfen , Xiong Bing , Ren Wenming , Hu Youhong , Chen Yi , Ai Jing
Published: April 2023

Supplementary Data
Supplementary file 2 from Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model
Authors: Funazo Tomoko , Tsuji Takahiro , Ozasa Hiroaki , Furugaki Koh , Yoshimura Yasushi , Oguri Tetsuya , Ajimizu Hitomi , Yasuda Yuto , Nomizo Takashi , Sakamori Yuichi , Yoshida Hironori , Kim Young Hak , Hirai Toyohiro
Published: April 2023

ABCC11 sequence inserted into the vector
Supplementary Data from Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model
Authors: Funazo Tomoko , Tsuji Takahiro , Ozasa Hiroaki , Furugaki Koh , Yoshimura Yasushi , Oguri Tetsuya , Ajimizu Hitomi , Yasuda Yuto , Nomizo Takashi , Sakamori Yuichi , Yoshida Hironori , Kim Young Hak , Hirai Toyohiro
Published: April 2023

Figure S1. Schematic representation of the ABCC11 expression vector. Figure S2. Sequence analysis of the tyrosine kinase coding region of anaplastic lymphoma kinase (ALK). Figure S3. Cell viability assay of alectinib in H2228 and H2228-AR1S cells under low-attachment conditions. Figure S4. Gene expression of the ABC transporters in the five cell types. Figure S5. Intracellular concentration of alectinib. Figure S6. Tumor images on day 11 of treatment. The tumor volume at 10 days after alectinib administration. Figure S7. ALK phosphorylation in KTOR1 and KOR1-RE cell exposed to alectinib for 3 hours as determined using immunoblotting. Figure S8. IC50 values of H2228 and H2228-AR1S cell lines in the presence of crizotinib, ceritinib, lorlatinib, and brigatinib. Table S1. Immunoblotting antibodies. Table S2. Primers used for ABC transporters purchased from Thermo Fisher Scientific. Table S3. siRNA oligonucleotides purchased from Thermo Fisher Scientific. Table S4. Primer sequences for direct sequencing of ALK exons. Table S5. IC50 for alectinib in H2228-AR1S cells transfected with negative control or ABCC11 siRNA. Table S6. IC50 for alectinib in KTOR1-RE cells transfected with negative control or ABCC11 siRNA.
Supplementary Figures 1-4 from Targeting the Synthetic Vulnerability of PTEN-Deficient Glioblastoma Cells with MCL1 Inhibitors
Authors: Chen Chao , Zhu Sichao , Zhang Xia , Zhou Tingting , Gu Jing , Xu Yurong , Wan Quan , Qi Xiao , Chai Yezi , Liu Xiaorong , Chen Lukui , Yan Jie , Hua Yunfen , Lin Fan
Published: April 2023

Supplemental Figure 1. Kaplan-Meier survival curves of glioma patients with positive or negative MCL1 expression (P-value by log-rank test). Supplemental Figure 2. Layout of apoptotic antibody array and results analysis. Supplemental Figure 3. Evaluation of the antiâ€�GBM effect of the combined treatment of UMIâ€�77 and temozolomide (U+T). Supplemental Figure 4. Combination treatment of temozolomide and UMI-77 in established GBM cell lines.
Table S2 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
Authors: Graziani Edmund I. , Sung Matthew , Ma Dangshe , Narayanan Bitha , Marquette Kimberly , Puthenveetil Sujiet , Tumey L. Nathan , Bikker Jack , Casavant Jeffrey , Bennett Eric M. , Charati Manoj B. , Golas Jonathon , Hosselet Christine , Rohde Cynthia M. , Hu George , Guffroy Magali , Falahatpisheh Hadi , Finkelstein Martin , Clark Tracey , Barletta Frank , Tchistiakova Lioudmila , Lucas Judy , Rosfjord Edward , Loganzo Frank , O'Donnell Christopher J. , Gerber Hans-Peter , Sapra Puja
Published: April 2023

In vitro cytotoxicity of PF-06804103 across a panel of cancer cell lines.
Supplementary Data from ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium
Authors: Hingorani Pooja , Roth Michael E. , Wang Yifei , Zhang Wendong , Gill Jonathan B. , Harrison Douglas J. , Teicher Beverly , Erickson Stephen , Gatto Gregory , Smith Malcolm A. , Kolb Edward A. , Gorlick Richard
Published: April 2023

Model Name, passage#, and time from implantation to testing
Supplementary Data from ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium
Authors: Hingorani Pooja , Roth Michael E. , Wang Yifei , Zhang Wendong , Gill Jonathan B. , Harrison Douglas J. , Teicher Beverly , Erickson Stephen , Gatto Gregory , Smith Malcolm A. , Kolb Edward A. , Gorlick Richard
Published: April 2023

LRRC15 Gene Expression across osteosarcoma PDX models
Supplementary Information from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
Authors: Graziani Edmund I. , Sung Matthew , Ma Dangshe , Narayanan Bitha , Marquette Kimberly , Puthenveetil Sujiet , Tumey L. Nathan , Bikker Jack , Casavant Jeffrey , Bennett Eric M. , Charati Manoj B. , Golas Jonathon , Hosselet Christine , Rohde Cynthia M. , Hu George , Guffroy Magali , Falahatpisheh Hadi , Finkelstein Martin , Clark Tracey , Barletta Frank , Tchistiakova Lioudmila , Lucas Judy , Rosfjord Edward , Loganzo Frank , O'Donnell Christopher J. , Gerber Hans-Peter , Sapra Puja
Published: April 2023

Includes Supplementary Materials and Methods, Data and Figure Legends
Supplementary Data from Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2
Authors: Kidger Andrew M. , Munck Joanne M. , Saini Harpreet K. , Balmanno Kathryn , Minihane Emma , Courtin Aurelie , Graham Brent , O'Reilly Marc , Odle Richard , Cook Simon J.
Published: April 2023

Supplementary Tables and Figures
Figure S1 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
Authors: Graziani Edmund I. , Sung Matthew , Ma Dangshe , Narayanan Bitha , Marquette Kimberly , Puthenveetil Sujiet , Tumey L. Nathan , Bikker Jack , Casavant Jeffrey , Bennett Eric M. , Charati Manoj B. , Golas Jonathon , Hosselet Christine , Rohde Cynthia M. , Hu George , Guffroy Magali , Falahatpisheh Hadi , Finkelstein Martin , Clark Tracey , Barletta Frank , Tchistiakova Lioudmila , Lucas Judy , Rosfjord Edward , Loganzo Frank , O'Donnell Christopher J. , Gerber Hans-Peter , Sapra Puja
Published: April 2023

In vivo efficacy of site-specific anti-HER2 vc0101 4 DAR ADCs in N87 xenograft tumor model.
Table S6-10 from PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis
Authors: Lim James T. , Singh Neha , Leuvano Libia A. , Calvert Valerie S. , Petricoin Emanuel F. , Teachey David T. , Lock Richard B. , Padi Megha , Kraft Andrew S. , Padi Sathish K.R.
Published: April 2023

Table S6:Functional enrichment of KEGG pathways in RNA-seq active module. Table S7: Testing for protein-protein interaction network bias in active module analysis with KEGG pathway functional enrichment (Trial 1). Table S8: Testing for protein-protein interaction network bias in active module analysis with KEGG pathway functional enrichment (Trial 2). Table S9: Testing for protein-protein interaction network bias in active module analysis with KEGG pathway functional enrichment (Trial 3). Table S10: Testing for protein-protein interaction network bias in active module analysis with KEGG pathway functional enrichment (Trial 4).
Supplementary Materials from Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer
Authors: Abderrahman Balkees , Maximov Philipp Y. , Curpan Ramona F. , Fanning Sean W. , Hanspal Jay S. , Fan Ping , Foulds Charles E. , Chen Yue , Malovannaya Anna , Jain Antrix , Xiong Rui , Greene Geoffrey L. , Tonetti Debra A. , Thatcher Gregory R.J. , Jordan V. Craig
Published: April 2023

Supplementary written materials including Supplementary figure/table legends
Table S4-5 from PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis
Authors: Lim James T. , Singh Neha , Leuvano Libia A. , Calvert Valerie S. , Petricoin Emanuel F. , Teachey David T. , Lock Richard B. , Padi Megha , Kraft Andrew S. , Padi Sathish K.R.
Published: April 2023

Table S4: GSEA curated canonical pathway enrichment (FDR<0.25) Table S5: GSEA oncogenic signature enrichment of AZDR1 compared to Naïve HSB-2 (FDR<0.25)
Supplementary Data from Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer
Authors: Abderrahman Balkees , Maximov Philipp Y. , Curpan Ramona F. , Fanning Sean W. , Hanspal Jay S. , Fan Ping , Foulds Charles E. , Chen Yue , Malovannaya Anna , Jain Antrix , Xiong Rui , Greene Geoffrey L. , Tonetti Debra A. , Thatcher Gregory R.J. , Jordan V. Craig
Published: April 2023

Table S1
Supplementary Data from Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer
Authors: Abderrahman Balkees , Maximov Philipp Y. , Curpan Ramona F. , Fanning Sean W. , Hanspal Jay S. , Fan Ping , Foulds Charles E. , Chen Yue , Malovannaya Anna , Jain Antrix , Xiong Rui , Greene Geoffrey L. , Tonetti Debra A. , Thatcher Gregory R.J. , Jordan V. Craig
Published: April 2023

Table S5
All Supplementary Figures from Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer
Authors: Abderrahman Balkees , Maximov Philipp Y. , Curpan Ramona F. , Fanning Sean W. , Hanspal Jay S. , Fan Ping , Foulds Charles E. , Chen Yue , Malovannaya Anna , Jain Antrix , Xiong Rui , Greene Geoffrey L. , Tonetti Debra A. , Thatcher Gregory R.J. , Jordan V. Craig
Published: April 2023

Supplementary figure/table materials except Table S1 and Table S5
Supplementary Figure 2 from Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer
Authors: Izumi Hiroki , Wang Zhiyong , Goto Yusuke , Ando Toshinori , Wu Xingyu , Zhang Xuefeng , Li Hua , Johnson Daniel E. , Grandis Jennifer R. , Gutkind J. Silvio
Published: April 2023

Supplementary Figure 2
Supplementary Figure 1 from Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer
Authors: Izumi Hiroki , Wang Zhiyong , Goto Yusuke , Ando Toshinori , Wu Xingyu , Zhang Xuefeng , Li Hua , Johnson Daniel E. , Grandis Jennifer R. , Gutkind J. Silvio
Published: April 2023

Supplementary Figure 1
Supplementary Data from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
Authors: McDonald Gabrielle , Chubukov Victor , Coco John , Truskowski Kevin , Narayanaswamy Rohini , Choe Sung , Steadman Mya , Artin Erin , Padyana Anil K. , Jin Lei , Ronseaux Sebastien , Locuson Charles , Fan Zi-Peng , Erdmann Tabea , Mann Alan , Hayes Sebastian , Fletcher Mark , Nellore Kavitha , Rao Siva Sanjeeva , Subramanya Hosahalli , Reddy K. Satish , Panigrahi Sunil K. , Antony Thomas , Gopinath Sreevalsam , Sui Zhihua , Nagaraja Nelamangala , Dang Lenny , Lenz Georg , Hurov Jonathan , Biller Scott A. , Murtie Josh , Marks Kevin M. , Ulanet Danielle B.
Published: April 2023

Supplementary methods, references and figures
Supplementary Data Table S2 from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
Authors: McDonald Gabrielle , Chubukov Victor , Coco John , Truskowski Kevin , Narayanaswamy Rohini , Choe Sung , Steadman Mya , Artin Erin , Padyana Anil K. , Jin Lei , Ronseaux Sebastien , Locuson Charles , Fan Zi-Peng , Erdmann Tabea , Mann Alan , Hayes Sebastian , Fletcher Mark , Nellore Kavitha , Rao Siva Sanjeeva , Subramanya Hosahalli , Reddy K. Satish , Panigrahi Sunil K. , Antony Thomas , Gopinath Sreevalsam , Sui Zhihua , Nagaraja Nelamangala , Dang Lenny , Lenz Georg , Hurov Jonathan , Biller Scott A. , Murtie Josh , Marks Kevin M. , Ulanet Danielle B.
Published: April 2023

Genome-wide CRISPR depletion screen data
Table S6 from Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance
Authors: Huang Zhiqing , Kondoh Eiji , Visco Zachary R. , Baba Tsukasa , Matsumura Noriomi , Dolan Emma , Whitaker Regina S. , Konishi Ikuo , Fujii Shingo , Berchuck Andrew , Murphy Susan K.
Published: April 2023

Functional annotations (from DAVID) for genes with higher expression in cells with low spheroid-forming capacity relative to cells with high spheroid-forming capacity.
Figure S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
Authors: Shorstova Tatiana , Su Jie , Zhao Tiejun , Dahabieh Michael , Leibovitch Matthew , De Sa Tavares Russo Mariana , Avizonis Daina , Rajkumar Shivshankari , Watson Ian R. , del Rincón Sonia V. , Miller Wilson H. , Foulkes William D. , Witcher Michael
Published: April 2023

Studies of TYMS, DUT and RRM1 expression and modulation in ovarian cancer cells
Figure S1 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
Authors: Shorstova Tatiana , Su Jie , Zhao Tiejun , Dahabieh Michael , Leibovitch Matthew , De Sa Tavares Russo Mariana , Avizonis Daina , Rajkumar Shivshankari , Watson Ian R. , del Rincón Sonia V. , Miller Wilson H. , Foulkes William D. , Witcher Michael
Published: April 2023

Re-expression of KRAS and BRAF confers resistance to BETi
Supplementary Data Figure S3 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
Authors: Skidmore Lillian , Sakamuri Sukumar , Knudsen Nick A. , Hewet Amha Gebre , Milutinovic Snezana , Barkho Wisam , Biroc Sandra Lyn , Kirtley Jessica , Marsden Robin , Storey Kristine , Lopez Ianina , Yu Wayne , Fang Shiao-Yan , Yao Sulan , Gu Yi , Tian Feng
Published: April 2023

Activity of ARX788 single or fractionated dosing in breast and gastric PDX models. After single or multiple-dose administration (dotted lines) of vehicle or ARX788, mean tumor volumes ({plus minus} SEM) are shown for a subset of (A) breast or (B) gastric cancer PDX models with HER2 positive or HER2 low expression. Statistical significance (p<0.05) versus vehicle was evaluated for each treatment group (n=8 mice/group).
Supplementary Data Figure S1 from ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
Authors: Skidmore Lillian , Sakamuri Sukumar , Knudsen Nick A. , Hewet Amha Gebre , Milutinovic Snezana , Barkho Wisam , Biroc Sandra Lyn , Kirtley Jessica , Marsden Robin , Storey Kristine , Lopez Ianina , Yu Wayne , Fang Shiao-Yan , Yao Sulan , Gu Yi , Tian Feng
Published: April 2023

Amino acid sequence of the antibody used in ARX788. The complementarity determining regions (CDRs) are underlined, and the pAF is depicted as a "U".
Supplementary Table 1 from Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma
Authors: Teh Jessica L.F. , Purwin Timothy J. , Han Anna , Chua Vivian , Patel Prem , Baqai Usman , Liao Connie , Bechtel Nelisa , Sato Takami , Davies Michael A. , Aguirre-Ghiso Julio , Aplin Andrew E.
Published: April 2023

Supplemental Table 1. RNA Seq z-score values for genes significantly up- or downregulated in MEKi-R or CDK4/6i-T groups compared to controls, corresponding to figure 3A. Data are indexed to show which genes are significant for each comparison (BHFDR < 0.05 and absolute log2(FC) > 1).
Supplementary Figures 1-5 from Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma
Authors: Teh Jessica L.F. , Purwin Timothy J. , Han Anna , Chua Vivian , Patel Prem , Baqai Usman , Liao Connie , Bechtel Nelisa , Sato Takami , Davies Michael A. , Aguirre-Ghiso Julio , Aplin Andrew E.
Published: April 2023

Supplemental Figure 1. CDK4/6i + MEKi treatment does not modulate proteins within the apoptotic signaling pathway. Supplemental Figure 2. Growth of UM001 xenografts treated with MEKi and/or CDK4/6i. Supplemental Figure 3. RNA-seq samples cluster based treatment. Supplemental Figure 4. MEKi, CDK4/6i, and OxPhosi have reversible effects. Supplemental Figure 5. Cleaved caspase 3 staining in UM001 xenograft tumors.
Supplementary Data from Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer
Authors: Zhang Yuchen , Ware Michael B. , Zaidi Mohammad Y. , Ruggieri Amanda N. , Olson Brian M. , Komar Hannah , Farren Matthew R. , Nagaraju Ganji Purnachandra , Zhang Chao , Chen Zhengjia , Sarmiento Juan M. , Ahmed Rafi , Maithel Shishir K. , El-Rayes Bassel F. , Lesinski Gregory B.
Published: April 2023

Supplemental Figures S1-S7
Figure S1-S4 from Perhexiline Demonstrates FYN-mediated Antitumor Activity in Glioblastoma
Authors: Kant Shiva , Kesarwani Pravin , Guastella Anthony R. , Kumar Praveen , Graham Stewart F. , Buelow Katie L. , Nakano Ichiro , Chinnaiyan Prakash
Published: April 2023

Supplementary Figures_Unmarked
Supplementary table 3 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
Authors: Heisey Daniel A.R. , Jacob Sheeba , Lochmann Timothy L. , Kurupi Richard , Ghotra Maninderjit S. , Calbert Marissa L. , Shende Mayuri , Maves Yuki Kato , Koblinski Jennifer E. , Dozmorov Mikhail G. , Boikos Sosipatros A. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

Gene symbols and names
Supplementary table 2 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
Authors: Heisey Daniel A.R. , Jacob Sheeba , Lochmann Timothy L. , Kurupi Richard , Ghotra Maninderjit S. , Calbert Marissa L. , Shende Mayuri , Maves Yuki Kato , Koblinski Jennifer E. , Dozmorov Mikhail G. , Boikos Sosipatros A. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

The sequences of the primers used for ChIP
Supplementary table 1 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
Authors: Heisey Daniel A.R. , Jacob Sheeba , Lochmann Timothy L. , Kurupi Richard , Ghotra Maninderjit S. , Calbert Marissa L. , Shende Mayuri , Maves Yuki Kato , Koblinski Jennifer E. , Dozmorov Mikhail G. , Boikos Sosipatros A. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

The sequences of the primers used for qPCR
Figure S7 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
Authors: Heisey Daniel A.R. , Jacob Sheeba , Lochmann Timothy L. , Kurupi Richard , Ghotra Maninderjit S. , Calbert Marissa L. , Shende Mayuri , Maves Yuki Kato , Koblinski Jennifer E. , Dozmorov Mikhail G. , Boikos Sosipatros A. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

The combination of GSK-J4 and THZ1 does not induce toxicity in mice
Supplementary Data from Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A
Authors: Thompson Peggy A. , Eam Boreth , Young Nathan P. , Fish Sarah , Chen Joan , Barrera Maria , Howard Haleigh , Sung Eric , Parra Ana , Staunton Jocelyn , Chiang Gary G. , Gerson-Gurwitz Adina , Wegerski Christopher J. , Nevarez Andres , Clarine Jeff , Sperry Samuel , Xiang Alan , Nilewski Christian , Packard Garrick K. , Michels Theodore , Tran Chinh , Sprengeler Paul A. , Ernst Justin T. , Reich Siegfried H. , Webster Kevin R.
Published: April 2023

Tables S1-S3, Figures S1-S5
Figure S6 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
Authors: Heisey Daniel A.R. , Jacob Sheeba , Lochmann Timothy L. , Kurupi Richard , Ghotra Maninderjit S. , Calbert Marissa L. , Shende Mayuri , Maves Yuki Kato , Koblinski Jennifer E. , Dozmorov Mikhail G. , Boikos Sosipatros A. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

THZ1 inhibits RNA polymerase II in ES tumor
Figure S5 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
Authors: Heisey Daniel A.R. , Jacob Sheeba , Lochmann Timothy L. , Kurupi Richard , Ghotra Maninderjit S. , Calbert Marissa L. , Shende Mayuri , Maves Yuki Kato , Koblinski Jennifer E. , Dozmorov Mikhail G. , Boikos Sosipatros A. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

GSK-J4 in combination with chemotherapeutic agents synergistically inhibit ES cells
Table S1 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Authors: Mizushima Taichi , Jiang Guiyang , Kawahara Takashi , Li Peng , Han Bin , Inoue Satoshi , Ide Hiroki , Kato Ikuma , Jalalizadeh Mehrsa , Miyagi Etsuko , Fukuda Mitsunori , Reis Leonardo O. , Miyamoto Hiroshi
Published: April 2023

PCR primers.
Figure S4 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
Authors: Heisey Daniel A.R. , Jacob Sheeba , Lochmann Timothy L. , Kurupi Richard , Ghotra Maninderjit S. , Calbert Marissa L. , Shende Mayuri , Maves Yuki Kato , Koblinski Jennifer E. , Dozmorov Mikhail G. , Boikos Sosipatros A. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

GSK-J4 inhibits EWS-FLI1 targets EZH2 and tumor growth
Figure S7 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Authors: Mizushima Taichi , Jiang Guiyang , Kawahara Takashi , Li Peng , Han Bin , Inoue Satoshi , Ide Hiroki , Kato Ikuma , Jalalizadeh Mehrsa , Miyagi Etsuko , Fukuda Mitsunori , Reis Leonardo O. , Miyamoto Hiroshi
Published: April 2023

Representative histological images of mouse xenografts of MB49-derived sublines.
Figure S3 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
Authors: Heisey Daniel A.R. , Jacob Sheeba , Lochmann Timothy L. , Kurupi Richard , Ghotra Maninderjit S. , Calbert Marissa L. , Shende Mayuri , Maves Yuki Kato , Koblinski Jennifer E. , Dozmorov Mikhail G. , Boikos Sosipatros A. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

GSK-J4 inhibits histone demethylation of EWS-FLI1 target genes
Figure S2 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
Authors: Heisey Daniel A.R. , Jacob Sheeba , Lochmann Timothy L. , Kurupi Richard , Ghotra Maninderjit S. , Calbert Marissa L. , Shende Mayuri , Maves Yuki Kato , Koblinski Jennifer E. , Dozmorov Mikhail G. , Boikos Sosipatros A. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

GSK-J4 alters EWS-FLI1 gene targets in ES
Figure S1 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
Authors: Heisey Daniel A.R. , Jacob Sheeba , Lochmann Timothy L. , Kurupi Richard , Ghotra Maninderjit S. , Calbert Marissa L. , Shende Mayuri , Maves Yuki Kato , Koblinski Jennifer E. , Dozmorov Mikhail G. , Boikos Sosipatros A. , Benes Cyril H. , Faber Anthony C.
Published: April 2023

EWS-FLI1 expression sensitizes cells to GSK-J4